Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of BMS-986165 Solid Tablet Formulations
NCT04536961Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deucravacitinib in plaque psoriasis (9 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration at Day 7, Time of maximum observed plasma concentration at Day 7 and 1 more. Started Sep 2020; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04536961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04536961.